Patient Satisfaction and Quality of Life Impact - PecFent®

Archimedes Development Ltd300 enrolled

Overview

National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions. • Study objectives include assessment of early treatment satisfaction.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Breakthrough Cancer Pain

Interventions

PecFent® (fentanyl) nasal sprayDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult (aged ≥18 years) with cancer * Taking at least 60 mg of oral morphine sulfate or equivalent per day for chronic background pain

Locations (1)

Centre Léon-Bérard

Lyon, France

RECRUITING

Outcomes

Primary Outcomes

Satisfaction

Satisfaction will be assessed using a 4-point Likert scale.

Time frame: Satisfaction will be assessed approximately 1 hour after each BTPc episode treated with PecFent® from completion of titration through Day 7

Central Contacts

Sylvie Allouche, MD

CONTACT

+33155702320 sylvieallouchecovarrubias@archimedespharma.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.